2015 Q2 Form 10-Q Financial Statement
#000156459015006101 Filed on August 05, 2015
Income Statement
| Concept | 2015 Q2 | 2014 Q2 |
|---|---|---|
| Revenue | $3.435B | $3.172B |
| YoY Change | 8.26% | 10.48% |
| Cost Of Revenue | $2.446B | $2.247B |
| YoY Change | 8.88% | 11.53% |
| Gross Profit | $988.5M | $926.0M |
| YoY Change | 6.75% | 8.0% |
| Gross Profit Margin | 28.78% | 29.19% |
| Selling, General & Admin | $354.2M | $301.8M |
| YoY Change | 17.36% | 12.03% |
| % of Gross Profit | 35.83% | 32.59% |
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | $158.8M | $145.9M |
| YoY Change | 8.84% | 11.72% |
| % of Gross Profit | 16.06% | 15.76% |
| Operating Expenses | $513.0M | $447.8M |
| YoY Change | 14.56% | 11.95% |
| Operating Profit | $480.5M | $484.3M |
| YoY Change | -0.77% | -7.23% |
| Interest Expense | -$147.3M | -$197.6M |
| YoY Change | -25.46% | 96.62% |
| % of Operating Profit | -30.65% | -40.8% |
| Other Income/Expense, Net | $2.311M | $1.693M |
| YoY Change | 36.5% | -223.22% |
| Pretax Income | $330.5M | $282.3M |
| YoY Change | 17.08% | -31.57% |
| Income Tax | $122.8M | $100.9M |
| % Of Pretax Income | 37.14% | 35.74% |
| Net Earnings | $170.5M | $147.7M |
| YoY Change | 15.43% | -41.94% |
| Net Earnings / Revenue | 4.96% | 4.66% |
| Basic Earnings Per Share | $0.80 | $0.70 |
| Diluted Earnings Per Share | $0.78 | $0.68 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 213.0M | 212.3M |
| Diluted Shares Outstanding | 217.6M | 216.7M |
Balance Sheet
| Concept | 2015 Q2 | 2014 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $1.906B | $1.485B |
| YoY Change | 28.32% | 137.6% |
| Cash & Equivalents | $933.7M | $1.421B |
| Short-Term Investments | $971.8M | $64.00M |
| Other Short-Term Assets | $189.5M | $164.6M |
| YoY Change | 15.15% | 9.57% |
| Inventory | $159.4M | $99.65M |
| Prepaid Expenses | ||
| Receivables | $1.667B | $1.550B |
| Other Receivables | $456.5M | $463.0M |
| Total Short-Term Assets | $4.781B | $4.161B |
| YoY Change | 14.89% | 32.87% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $2.565B | $2.291B |
| YoY Change | 11.97% | 15.06% |
| Goodwill | $9.254B | |
| YoY Change | 2.18% | |
| Intangibles | $2.023B | |
| YoY Change | -2.6% | |
| Long-Term Investments | $160.0M | $130.0M |
| YoY Change | 23.08% | 28.71% |
| Other Assets | $122.0M | $66.11M |
| YoY Change | 84.55% | -32.47% |
| Total Long-Term Assets | $14.17B | $13.76B |
| YoY Change | 2.92% | 3.31% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $4.781B | $4.161B |
| Total Long-Term Assets | $14.17B | $13.76B |
| Total Assets | $18.95B | $17.93B |
| YoY Change | 5.7% | 8.93% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $490.0M | $405.8M |
| YoY Change | 20.76% | 26.77% |
| Accrued Expenses | $679.0M | $627.0M |
| YoY Change | 8.29% | 12.97% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $292.0M |
| YoY Change | -100.0% | |
| Long-Term Debt Due | $109.0M | $117.1M |
| YoY Change | -6.9% | -51.62% |
| Total Short-Term Liabilities | $2.334B | $2.608B |
| YoY Change | -10.51% | 17.76% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $9.101B | $8.391B |
| YoY Change | 8.46% | 1.91% |
| Other Long-Term Liabilities | $400.0M | $386.0M |
| YoY Change | 3.62% | 7.2% |
| Total Long-Term Liabilities | $9.501B | $386.0M |
| YoY Change | 2361.19% | 7.2% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $2.334B | $2.608B |
| Total Long-Term Liabilities | $9.501B | $386.0M |
| Total Liabilities | $13.80B | $12.21B |
| YoY Change | 13.04% | 5.49% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | $3.695B | |
| YoY Change | -8.0% | |
| Common Stock | $215.0K | |
| YoY Change | 59.26% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $5.147B | $4.786B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $18.95B | $17.93B |
| YoY Change | 5.7% | 8.93% |
Cashflow Statement
| Concept | 2015 Q2 | 2014 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $170.5M | $147.7M |
| YoY Change | 15.43% | -41.94% |
| Depreciation, Depletion And Amortization | $158.8M | $145.9M |
| YoY Change | 8.84% | 11.72% |
| Cash From Operating Activities | $31.40M | $262.4M |
| YoY Change | -88.03% | -14.47% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $169.5M | $152.0M |
| YoY Change | 11.46% | -207.29% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$525.6M | -$95.10M |
| YoY Change | 452.68% | 57.97% |
| Cash From Investing Activities | -$695.0M | -$247.1M |
| YoY Change | 181.26% | 22.39% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 586.0M | 298.7M |
| YoY Change | 96.18% | -260.33% |
| NET CHANGE | ||
| Cash From Operating Activities | 31.40M | 262.4M |
| Cash From Investing Activities | -695.0M | -247.1M |
| Cash From Financing Activities | 586.0M | 298.7M |
| Net Change In Cash | -77.60M | 314.0M |
| YoY Change | -124.71% | -485.75% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $31.40M | $262.4M |
| Capital Expenditures | $169.5M | $152.0M |
| Free Cash Flow | -$138.1M | $110.4M |
| YoY Change | -225.08% | -75.39% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
6306191000 | ||
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
5289745000 | ||
| CY2015Q2 | us-gaap |
Profit Loss
ProfitLoss
|
207777000 | |
| CY2014Q2 | us-gaap |
Profit Loss
ProfitLoss
|
181421000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
131629000 | ||
| us-gaap |
Health Care Organization Revenue
HealthCareOrganizationRevenue
|
6215265000 | ||
| us-gaap |
Loss Contingency Loss In Period
LossContingencyLossInPeriod
|
495000000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
416392000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
925520000 | ||
| us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
201640000 | ||
| us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
212467000 | ||
| dva |
Debt Redemption And Refinancing Charges
DebtRedemptionAndRefinancingCharges
|
48072000 | ||
| dva |
Debt Redemption And Refinancing Charges
DebtRedemptionAndRefinancingCharges
|
97548000 | ||
| CY2015Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2311000 | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1778000 | ||
| CY2015Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
330539000 | |
| CY2015Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
122762000 | |
| CY2014Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
100887000 | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
36829000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
225738000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
393158000 | ||
| CY2015Q2 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
37300000 | |
| CY2014Q2 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
33738000 | |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
71769000 | ||
| CY2015Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
170477000 | |
| CY2015Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.80 | |
| CY2015Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.78 | |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
212991606 | |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
217606198 | |
| CY2015Q3 | dei |
Entity Public Float
EntityPublicFloat
|
17000000000 | |
| CY2014Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
2688194000 | |
| CY2015Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
480548000 | |
| CY2014Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
484295000 | |
| CY2015Q2 | us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
104248000 | |
| dva |
Patient Care Costs
PatientCareCosts
|
4808688000 | ||
| us-gaap |
Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
|
314581000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
3391000 | ||
| CY2014Q2 | us-gaap |
Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
|
2099197000 | |
| CY2015Q3 | us-gaap |
Health Care Organization Capitation Revenue
HealthCareOrganizationCapitationRevenue
|
926847000 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
693826000 | ||
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
3986000 | ||
| CY2014Q2 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
3208000 | |
| us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
7941000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
582697000 | ||
| CY2014Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
298636000 | |
| CY2014Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1693000 | |
| dva |
Patient Care Costs
PatientCareCosts
|
4426310000 | ||
| CY2014Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
6095000 | |
| CY2015Q2 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
2159000 | |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
5719000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
312632000 | ||
| CY2014Q2 | us-gaap |
Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
|
88052000 | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
288486000 | ||
| us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
13467000 | ||
| CY2015Q3 | us-gaap |
Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
|
2304582000 | |
| CY2015Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
158843000 | |
| CY2014Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
145907000 | |
| CY2015Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
5033000 | |
| CY2015Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
2954070000 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
216420713 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
283000 | ||
| CY2014Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
|
-4997000 | |
| us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
|
-1601000 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
213188268 | ||
| CY2014Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
147683000 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.28 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
909000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
618896000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
|
-8213000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
|
-7714000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
59860000 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.56 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.53 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
211817893 | ||
| us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
173000 | ||
| CY2014Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
282308000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
168458000 | ||
| CY2014Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
212258994 | |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
216720944 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
217790617 | ||
| us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
|
-8356000 | ||
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
62186000 | ||
| CY2014Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
578000 | |
| us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
207000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
330972000 | ||
| CY2014Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.70 | |
| CY2014Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.68 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.27 | ||
| CY2014Q2 | us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
106132000 | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-947337000 | ||
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
28144986000 | ||
| us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
27476994000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
334283000 | ||
| us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
62186000 | ||
| CY2015Q2 | us-gaap |
Assets Current
AssetsCurrent
|
4780921000 | |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
3876797000 | |
| CY2015Q2 | dva |
Debt Redemption And Refinancing Charges
DebtRedemptionAndRefinancingCharges
|
48072000 | |
| CY2014Q2 | dva |
Debt Redemption And Refinancing Charges
DebtRedemptionAndRefinancingCharges
|
97548000 | |
| us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
3311000 | ||
| CY2015Q2 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
239012000 | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
240626000 | |
| CY2014Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1939000 | |
| CY2015Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-99000 | |
| CY2015Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
16000 | |
| CY2015Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
5025000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-12860000 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1967000 | ||
| CY2015Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
3246000 | |
| CY2014Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
2305000 | |
| us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-19362000 | ||
| CY2015Q2 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
211023000 | |
| CY2014Q2 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
183726000 | |
| us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
112267000 | ||
| us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
396469000 | ||
| CY2015Q2 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
37300000 | |
| CY2014Q2 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
33738000 | |
| us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
71769000 | ||
| CY2015Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
173723000 | |
| CY2014Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
149988000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
40498000 | ||
| CY2015Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
933735000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
965241000 | |
| CY2015Q2 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
942141000 | |
| CY2014Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
337399000 | |
| CY2015Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1666969000 | |
| CY2014Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1525849000 | |
| CY2015Q2 | us-gaap |
Inventory Net
InventoryNet
|
159353000 | |
| CY2014Q4 | us-gaap |
Inventory Net
InventoryNet
|
136085000 | |
| CY2015Q2 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
456502000 | |
| CY2014Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
400916000 | |
| CY2015Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
189528000 | |
| CY2014Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
186842000 | |
| CY2015Q2 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
193681000 | |
| CY2014Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
83839000 | |
| us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
28040000 | ||
| us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
42110000 | ||
| us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
58539000 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
84113000 | ||
| us-gaap |
Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
|
79040000 | ||
| us-gaap |
Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
|
16913000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
4680000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
475093000 | ||
| us-gaap |
Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
|
18040000 | ||
| us-gaap |
Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
|
933000 | ||
| us-gaap |
Payments To Minority Shareholders
PaymentsToMinorityShareholders
|
10840000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-793000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-31506000 | ||
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
946249000 | |
| us-gaap |
Loss Contingency Disclosures
LossContingencyDisclosures
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contingencies</p></td></tr></table></div> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</p> <p style="margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inquiries by the Federal Government and Certain Related Civil Proceedings</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vainer Private Civil Suit</font>: In December 2008, the Company received a subpoena for documents from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company was advised by the U.S. Attorney’s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the federal government would not be intervening and not pursuing the relators’ allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended civil complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The amended complaint alleged that the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. The amended complaint sought monetary damages and civil penalties as well as costs and expenses. The parties completed discovery in early 2014; however, in August 2014, the Court granted relators’ motion for sanctions and reopened discovery on a limited basis. In June 2015, the Company finalized the terms of the settlement with plaintiffs, including a settlement amount of $450,000 and attorney fees and other costs of $45,000. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2011 U.S. Attorney Medicaid Investigation</font>: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request related to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company’s understanding that this inquiry is civil in nature. The Company understands further that certain other providers that operate dialysis clinics in New York may have received a similar request for documents. The Company has cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle with the government to resolve this matter, and is currently in the process of working with the government to finalize the specific terms of the settlement, and has accrued an amount that is immaterial.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Swoben Private Civil Suit</font>: In April 2013, the Company’s HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act (FCA) and the California False Claims Act, James M. Swoben, as relator, filed a <font style="font-style:italic;">qui tam</font> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal FCA and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services (CMS). In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court’s disposition of the appeal is pending.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Attorney Transportation Investigation</font>: In February 2015, the Company announced that it received six subpoenas from the OIG for medical records from six different dialysis centers in southern California operated by the Company. Specifically, each subpoena seeks the medical records of a single patient of the respective dialysis center. The Company has been advised by an attorney with the Civil Division of the United States Attorney’s Office for the Central District of California that the subpoenas relate to an investigation concerning the medical necessity of patient transportation.  The Company does not provide transportation or bill for the transport of its dialysis patients.  The Company does not know the scope of the investigation by the government, nor what conduct or activities might be the subject of the investigation.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. OIG Medicare Advantage Civil Investigation</font>: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of HCP, received a subpoena from the OIG. The Company has been advised by an attorney with the Civil Division of the United States Department of Justice in Washington, D.C. that the subpoena relates to an ongoing civil investigation concerning Medicare Advantage service providers’ risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain Medicare Advantage plans for which JSA provided services. It also requests information regarding JSA’s communications about patient diagnoses as they relate to certain Medicare Advantage plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government’s investigation.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the subpoena described above, in June 2015, the Company received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company’s and its subsidiaries’ (including HealthCare Partners and its subsidiary JSA HealthCare Corporation) provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into Medicare Advantage patient diagnosis coding and risk adjustment practices and potential overpayments by the government. Some of the information requested relates to what the Company disclosed in the risk factors of the Company’s quarterly report on Form 10-Q for the first quarter of 2015 as a potentially improper historical HCP coding practice related to a particular condition. The practice in question was discontinued following the Company’s November 1, 2012 acquisition of HCP and, as the Company previously disclosed, the Company notified CMS of the coding practice and potential overpayments. In connection with the HCP merger, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company would pursue an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred. The Company can make no assurances that the indemnification and escrow would cover the full amount of the Company’s potential losses related to this matter. The Company is cooperating with the government and will gather and produce the requested information. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and if criminal proceedings were initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any. </p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shareholder Derivative Claims </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">DaVita HealthCare Partners Inc. Derivative Litigation</font>: On January 7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May 17, 2013 and the Clark Shareholder action filed on August 7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that the Company’s directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations described above, the Vainer <font style="font-style:italic;">qui tam</font> private civil suit described above and the Woodard <font style="font-style:italic;">qui tam</font> private civil suit for which the Company previously announced a settlement in July 2012. The Company has entered into a settlement with the lead plaintiff, subject to court approval. The terms of the settlement, which were described in a court-ordered notice sent to shareholders in late January 2015, include enhancements to the Company’s corporate governance practices and provides that the Company will not oppose the derivative plaintiff’s application for an award of fees and expenses, the dollar amount of which is not material to the Company. On January 8, 2015, the Court entered an order preliminarily approving the settlement, directing that the notice to shareholders be provided as described above and held a settlement fairness hearing on May 1, 2015. During the fairness hearing, the Court approved the settlement and entered an order granting final approval of the settlement on June 5, 2015 and final judgment in the case was entered on June 9, 2015.</p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court’s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company’s condensed consolidated financial statements. In June 2015, the Company reached an agreement in principle to resolve the remainder of the claims in this litigation. The settlement must be approved by the court, and the parties are in the process of seeking that approval. The amount of the settlement is not material to the Company’s condensed consolidated financial statements. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows. </p></div> | ||
| us-gaap |
Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1<font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">New accounting standards</p></td></tr></table></div> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the FASB issued Accounting Standards Updated (ASU) No. 2015-11, <font style="font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory. </font>The amendments in this ASU apply to all inventory with the exception of inventory measured using last-in, first-out or the retail inventory method. This ASU simplifies the measurement of inventory. Under this new standard, inventory should be measured using the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonable predictable costs of completion, disposal and transportation. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016 and should be applied prospectively. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s condensed consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2015, the FASB issued ASU No. 2015-03, <font style="font-style:italic;">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font>. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendments in this ASU are effective for the Company beginning January 1, 2016. Early adoption is permitted. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The adoption of this standard will not have a material impact on the Company’s condensed consolidated financial statements.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2015, the FASB issued ASU No. 2015-05, <font style="font-style:italic;">Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement</font>, which amends ASC 350-40, Intangibles-Goodwill and Other-Internal-Use Software. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license. If an arrangement includes a software license, the accounting for the license will be consistent with licenses of other intangible assets. If the arrangement does not include a license, the arrangement will be accounted for as a service contract. The effective date will be the first quarter of fiscal year 2017 and can be adopted prospectively or retrospectively. The adoption of this standard will not have a material impact on the Company’s condensed consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2015, the FASB issued ASU No. 2015-02, <font style="font-style:italic;">Consolidation (Topic 810): Amendments to the Consolidation Analysis</font>. The amendments in the ASU clarify consolidation of VIEs regarding which reporting entity consolidates the legal entity. The amendments in the ASU are effective for the Company January 1, 2016. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s condensed consolidated financial statements.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard as issued is effective for the Company on January 1, 2017. In July 2015, the FASB approved a one-year deferral of the effective date. The final ASU now permits the Company to adopt this standard on January 1, 2018. Early application is permitted as of the initial effective date of January 1, 2017, but not prior to that date. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"> </p></div> | ||
| CY2015Q2 | dva |
Weighted Average Number Basic Shares Outstanding Adjustment
WeightedAverageNumberBasicSharesOutstandingAdjustment
|
215186000 | |
| CY2014Q2 | dva |
Weighted Average Number Basic Shares Outstanding Adjustment
WeightedAverageNumberBasicSharesOutstandingAdjustment
|
214451000 | |
| CY2014Q2 | dva |
Stock Issued Or Vested During Period Shares Stock Awards
StockIssuedOrVestedDuringPeriodSharesStockAwards
|
2000 | |
| dva |
Stock Issued Or Vested During Period Shares Stock Awards
StockIssuedOrVestedDuringPeriodSharesStockAwards
|
2000 | ||
| CY2015Q2 | us-gaap |
Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
|
2194000 | |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
|
2194000 | |
| CY2015Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
2420000 | |
| CY2014Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
2268000 | |
| CY2015Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
691000 | |
| CY2014Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
990000 | |
| CY2015Q2 | dva |
Percentage Of Outstanding Patient Accounts Receivables
PercentageOfOutstandingPatientAccountsReceivables
|
1.00 | |
| dva |
Accounts Receivable Period Outstanding
AccountsReceivablePeriodOutstanding
|
P3M | ||
| us-gaap |
Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
|
23123000 | ||
| CY2015Q2 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
940589000 | |
| CY2015Q2 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
31238000 | |
| CY2015Q2 | us-gaap |
Marketable Securities
MarketableSecurities
|
971827000 | |
| CY2014Q4 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
335975000 | |
| CY2014Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
28123000 | |
| CY2014Q4 | us-gaap |
Marketable Securities
MarketableSecurities
|
364098000 | |
| CY2015Q2 | us-gaap |
Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
|
940589000 | |
| CY2015Q2 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
1552000 | |
| CY2015Q2 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
29686000 | |
| CY2015Q2 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
29686000 | |
| CY2015Q2 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
|
5358000 | |
| CY2014Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
|
5181000 | |
| us-gaap |
Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
|
385000 | ||
| us-gaap |
Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
|
1277000 | ||
| us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
|
284000 | ||
| us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
|
340000 | ||
| CY2013Q4 | us-gaap |
Goodwill
Goodwill
|
9212974000 | |
| CY2014 | us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
221514000 | |
| CY2014 | us-gaap |
Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
|
1851000 | |
| CY2014 | us-gaap |
Goodwill Translation Adjustments
GoodwillTranslationAdjustments
|
-17342000 | |
| us-gaap |
Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
|
51075000 | ||
| us-gaap |
Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
|
446000 | ||
| us-gaap |
Goodwill Translation Adjustments
GoodwillTranslationAdjustments
|
-14978000 | ||
| us-gaap |
Goodwill Impaired Change In Estimate Description
GoodwillImpairedChangeInEstimateDescription
|
For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 1.8%, 1.9% and 2.0%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 4.2%, 3.1% and 3.6%, respectively. | ||
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | ||
| dva |
Increase Decrease In Prior Year Estimates Of Health Care Costs Payable
IncreaseDecreaseInPriorYearEstimatesOfHealthCareCostsPayable
|
838000 | ||
| CY2015Q2 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
34879000 | |
| us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
3002000 | ||
| CY2014Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
31877000 | |
| CY2015Q2 | us-gaap |
Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
|
1000000000 | |
| CY2015Q2 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
10337000 | |
| CY2014Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
10123000 | |
| CY2015Q2 | us-gaap |
Senior Notes
SeniorNotes
|
4500000000 | |
| CY2014Q4 | us-gaap |
Senior Notes
SeniorNotes
|
3775000000 | |
| CY2015Q2 | dva |
Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
|
62641000 | |
| CY2014Q4 | dva |
Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
|
69045000 | |
| CY2015Q2 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
247128000 | |
| CY2014Q4 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
218097000 | |
| CY2015Q2 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
9224769000 | |
| CY2014Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
8519642000 | |
| CY2015Q2 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
14922000 | |
| CY2014Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
16208000 | |
| CY2015Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
|
9209847000 | |
| CY2014Q4 | us-gaap |
Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
|
8503434000 | |
| CY2015Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
|
56484000 | |
| CY2015Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo
|
119993000 | |
| CY2015Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree
|
149031000 | |
| CY2015Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour
|
159637000 | |
| CY2015Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Five
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive
|
734147000 | |
| CY2015Q2 | dva |
Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Six
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearSix
|
57876000 | |
| CY2015Q2 | dva |
Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Seven And Thereafter
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearSevenAndThereafter
|
7947601000 | |
| CY2015Q2 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.0442 | |
| CY2015Q2 | us-gaap |
Longterm Debt Weighted Average Interest Rate
LongtermDebtWeightedAverageInterestRate
|
0.0438 | |
| CY2015Q2 | us-gaap |
Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
|
3000000 | |
| us-gaap |
Unrecorded Unconditional Purchase Obligation Description
UnrecordedUnconditionalPurchaseObligationDescription
|
Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years. | ||
| dva |
Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
|
69692000 | ||
| dva |
Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
|
52960000 | ||
| dva |
Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
|
10028000 | ||
| dva |
Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
|
10997000 | ||
| CY2015Q2 | dva |
Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net
LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet
|
161079000 | |
| CY2015Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
82577000 | |
| dva |
Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition
LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition
|
P1Y1M6D | ||
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y4M24D | ||
| us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
1067000 | ||
| us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
84113000 | ||
| us-gaap |
Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
|
78.82 | ||
| CY2015Q2 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
725944000 | |
| CY2010Q4 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
274056000 | |
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
2 | ||
| CY2015Q2 | dva |
Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
|
3425000 | |
| CY2014Q2 | dva |
Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
|
3781000 | |
| dva |
Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
|
9558000 | ||
| dva |
Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
|
4887000 | ||
| CY2015Q2 | us-gaap |
Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
|
0.50 | |
| CY2015Q2 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
169452000 | |
| CY2014Q2 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
152031000 | |
| CY2015Q2 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
-8421000 | |
| CY2014Q2 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
1181000 | |
| us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
-8421000 | ||
| us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
1472000 | ||
| CY2015Q2 | dva |
Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests
NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests
|
162056000 | |
| CY2014Q2 | dva |
Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests
NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests
|
148864000 | |
| dva |
Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests
NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests
|
51439000 | ||
| dva |
Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests
NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests
|
332444000 | ||
| CY2015Q2 | dva |
Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
|
152320000 | |
| CY2014Q2 | dva |
Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
|
203680000 | |
| dva |
Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
|
249712000 | ||
| dva |
Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
|
310015000 | ||
| CY2015Q2 | dva |
Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
|
2180217000 | |
| CY2015Q2 | us-gaap |
Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
|
281811000 | |
| CY2015Q2 | dva |
Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
|
10402486000 | |
| CY2014Q4 | dva |
Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
|
1385707000 | |
| CY2014Q4 | us-gaap |
Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
|
232026000 | |
| CY2014Q4 | dva |
Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
|
9663787000 | |
| us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
309902000 | ||
| dva |
Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
|
614820000 | ||
| dva |
Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
|
667992000 | ||
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-192899000 | ||
| us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
288340000 | ||
| dva |
Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
|
66035000 | ||
| dva |
Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
|
348436000 | ||
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-111788000 |
